Skip to content

Clinical Applications for Dobutamine Stress Echocardiography in Heart Failure Patients With Reduced Ejection Fraction Undergoing Atrial Fibrillation Ablation.

Clinical Applications for Dobutamine Stress Echocardiography in Heart Failure Patients With Reduced Ejection Fraction Undergoing Atrial Fibrillation Ablation.

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025827
Enrollment
Unknown
Registered
2019-09-10
Start date
2019-11-01
Completion date
Unknown
Last updated
2019-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atrial fibrillation

Interventions

The group of Dobutamine Stress Echocardiography(+):Catheter ablation of atrial fibrillation
The group of Dobutamine Stress Echocardiography(-):Catheter ablation of atrial fibrillation

Sponsors

The First Affilated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients had to have paroxysmal or persistent atrial fibrillation; an absence of response to, unacceptable side effects from, or unwillingness to take antiarrhythmic drugs; and New York Heart Association (NYHA) class II-IV heart failure and a left ventricular ejection fraction (LVEF) of 40% or less.

Exclusion criteria

Exclusion criteria: MI, CABG or PCI within preceding 3 months;Left atrial diameter >50mm; History of heart surgery or any previous ablation for AF; Intracardiac thrombus;Contradictions to anticoagulation; Females who are pregnant or breast feeding; Other severe cardiac dysfunction, cardiac ion channel diseases, inherited arrhythmogenic diseases and so on; Complicated with other severe diseases (e.g. hepatic and renal dysfunction, malignant tumor); Be allergic to iodine contrast medium.

Design outcomes

Primary

MeasureTime frame
Freedom from AF/AFL/AT recurrences at 12 months following ablation, without antiarrhythmic drug (type I/III) therapy;

Secondary

MeasureTime frame
Freedom from AF/AFL/AT recurrences at 12 months following ablation, with or without antiarrhythmic drug (type I/III) therapy;Proportion of patients with AF/AFL/ATa occurring during the first 90 days post ablation;Trends in NYHA class, LVEF, 6-minute walk distance, and left atrial diameter during follow-up;Quality of life measurements (SF-36);

Countries

China

Contacts

Public ContactXiaomeng Yin

The First Affilated Hospital of Dalian Medical University

dr.yinxm@163.com+86 18098875778

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026